Healthcare provider profile · identity verified

Gretta Carroll, M.D.

Family Practice · HOLLOMAN AFB, NM · NPI 1619358900

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	471	135
Levothyroxine Sodium	Levothyroxine Sodium	279	76
Amlodipine Besylate	Amlodipine Besylate	245	75
Gabapentin	Gabapentin	195	55
Lisinopril	Lisinopril	185	60
Losartan Potassium	Losartan Potassium	181	53
Rosuvastatin Calcium	Rosuvastatin Calcium	181	50
Omeprazole	Omeprazole	178	53
Pantoprazole Sodium	Pantoprazole Sodium	128	41
Metformin Hcl	Metformin Hcl	125	41
Furosemide	Furosemide	119	38
Metoprolol Succinate	Metoprolol Succinate	110	31
Duloxetine Hcl	Duloxetine Hcl	109	30
Alprazolam	Alprazolam	105	29
Sertraline Hcl	Sertraline Hcl	104	26
Hydrochlorothiazide	Hydrochlorothiazide	102	25
Trazodone Hcl	Trazodone Hcl	97	32
Albuterol Sulfate Hfa	Albuterol Sulfate	91	43
Escitalopram Oxalate	Escitalopram Oxalate	90	25
Potassium Chloride	Potassium Chloride	90	22
Buspirone Hcl	Buspirone Hcl	87	29
Simvastatin	Simvastatin	87	23
Tramadol Hcl	Tramadol Hcl	86	34
Venlafaxine Hcl Er	Venlafaxine Hcl	73	24
Montelukast Sodium	Montelukast Sodium	70	24
Citalopram Hbr	Citalopram Hydrobromide	68	21
Metoprolol Tartrate	Metoprolol Tartrate	68	22
Warfarin Sodium	Warfarin Sodium	66	16
Tizanidine Hcl	Tizanidine Hcl	65	20
Eliquis	Apixaban	63	19
Celecoxib	Celecoxib	61	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	61	18
Fluticasone Propionate	Fluticasone Propionate	60	26
Carvedilol	Carvedilol	59	17
Clopidogrel	Clopidogrel Bisulfate	58	22
Pregabalin	Pregabalin	56	17
Arexvy	Rsvpref3 Antigen/As01e/Pf	54	54
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	21
Ropinirole Hcl	Ropinirole Hcl	49	12
Meloxicam	Meloxicam	48	18
Metformin Hcl Er	Metformin Hcl	48	16
Pravastatin Sodium	Pravastatin Sodium	46	18
Zolpidem Tartrate	Zolpidem Tartrate	45	22
Famotidine	Famotidine	44	15
Fluoxetine Hcl	Fluoxetine Hcl	44	15
Hydroxyzine Hcl	Hydroxyzine Hcl	44	13
Prednisone	Prednisone	44	30
Jardiance	Empagliflozin	42	13
Baclofen	Baclofen	41	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	39	14
Fenofibrate	Fenofibrate Nanocrystallized	38	suppressed
Atenolol	Atenolol	37	suppressed
Bupropion Xl	Bupropion Hcl	37	13
Ezetimibe	Ezetimibe	37	13
Alendronate Sodium	Alendronate Sodium	35	16
Mirtazapine	Mirtazapine	35	12
Ozempic	Semaglutide	34	suppressed
Allopurinol	Allopurinol	32	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Cephalexin	Cephalexin	29	22
Glipizide Er	Glipizide	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	21
Trulicity	Dulaglutide	27	suppressed
Azelastine Hcl	Azelastine Hcl	25	suppressed
Mounjaro	Tirzepatide	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	24	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Aripiprazole	Aripiprazole	22	suppressed
Doxepin Hcl	Doxepin Hcl	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	17
Lidocaine	Lidocaine	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	18
Azithromycin	Azithromycin	19	15
Breyna	Budesonide/Formoterol Fumarate	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Glimepiride	Glimepiride	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Methylprednisolone	Methylprednisolone	16	14
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Benzonatate	Benzonatate	14	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	14	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Glipizide	Glipizide	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Hyoscyamine Sulfate	Hyoscyamine Sulfate	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Paroxetine Cr	Paroxetine Hcl	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error